RU2016123361A - Композиции, включающие клетки плацентарного перфузата человека - Google Patents

Композиции, включающие клетки плацентарного перфузата человека Download PDF

Info

Publication number
RU2016123361A
RU2016123361A RU2016123361A RU2016123361A RU2016123361A RU 2016123361 A RU2016123361 A RU 2016123361A RU 2016123361 A RU2016123361 A RU 2016123361A RU 2016123361 A RU2016123361 A RU 2016123361A RU 2016123361 A RU2016123361 A RU 2016123361A
Authority
RU
Russia
Prior art keywords
cells
composition
composition according
subject
perfusion solution
Prior art date
Application number
RU2016123361A
Other languages
English (en)
Russian (ru)
Inventor
Джоди П. ГЕРНИ
Сяокуй ЧЖАН
Стейси ХЕРБ
Роберт Дж. ХЭРИРИ
Original Assignee
Антродженезис Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Антродженезис Корпорейшн filed Critical Антродженезис Корпорейшн
Publication of RU2016123361A publication Critical patent/RU2016123361A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/50Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2016123361A 2013-11-15 2014-11-14 Композиции, включающие клетки плацентарного перфузата человека RU2016123361A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361905076P 2013-11-15 2013-11-15
US201361905077P 2013-11-15 2013-11-15
US61/905,076 2013-11-15
US61/905,077 2013-11-15
PCT/US2014/065665 WO2015073800A2 (en) 2013-11-15 2014-11-14 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses

Publications (1)

Publication Number Publication Date
RU2016123361A true RU2016123361A (ru) 2017-12-20

Family

ID=53058264

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016123361A RU2016123361A (ru) 2013-11-15 2014-11-14 Композиции, включающие клетки плацентарного перфузата человека

Country Status (11)

Country Link
US (2) US20160279171A1 (enExample)
EP (1) EP3068432A4 (enExample)
JP (4) JP2016537362A (enExample)
KR (3) KR20210121277A (enExample)
CN (2) CN105916521A (enExample)
AU (3) AU2014348454A1 (enExample)
CA (1) CA2930573C (enExample)
MX (2) MX2016006270A (enExample)
RU (1) RU2016123361A (enExample)
WO (1) WO2015073800A2 (enExample)
ZA (1) ZA201603270B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707491B2 (en) * 2016-11-11 2023-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods of treating neurodegenerative disorders
ES2977897T3 (es) * 2017-03-15 2024-09-02 Orca Biosystems Inc Composiciones y métodos para trasplantes de células madre hematopoyéticas
CN113395972A (zh) * 2018-11-30 2021-09-14 细胞结构公司 胎盘源性同种异体car-t细胞及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2305795B1 (en) 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
AU2002243980B2 (en) * 2001-02-14 2007-08-23 Robert J. Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
WO2002064755A2 (en) * 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20080063652A1 (en) * 2004-03-29 2008-03-13 Cytomatrix, Llc Methods for Production of Regulatory T Cells and Uses Thereof
EP1957633B1 (en) * 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
WO2007079184A2 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
EP2471903B1 (en) * 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
NZ570614A (en) * 2006-01-23 2012-07-27 Athersys Inc Multipotent adult progenitor cell treatment of brain injuries and diseases
JP5260499B2 (ja) * 2006-05-11 2013-08-14 コード ブラッド サイエンス インコーポレイテッド 臍帯血幹細胞の回収方法及び使用方法
KR20090076989A (ko) * 2006-10-23 2009-07-13 안트로제네시스 코포레이션 태반 줄기세포군으로 뼈의 결함을 치료하기 위한 방법과 조성물
JP2010518812A (ja) * 2007-02-12 2010-06-03 アンスロジェネシス コーポレーション 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにcd34+、cd45−胎盤幹細胞の濃縮細胞集団
US8273526B2 (en) * 2007-06-18 2012-09-25 Children's Hospital & Research Center At Oakland Method of isolating stem and progenitor cells from placenta
EP2205719A1 (en) * 2007-09-26 2010-07-14 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
US8263065B2 (en) * 2007-09-28 2012-09-11 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
AU2009316376B2 (en) * 2008-11-21 2015-08-20 Celularity Inc. Treatment of diseases, disorders or conditions of the lung using placental cells
WO2010105144A2 (en) * 2009-03-12 2010-09-16 University Of South Florida Method of disease-induced and receptor-mediated stem cell neuroprotection
WO2010141654A1 (en) * 2009-06-05 2010-12-09 Anthrogenesis Corporation Improved method of collecting placental cells
WO2011008277A2 (en) * 2009-07-14 2011-01-20 Massachusetts Institute Of Technology Hematopoietic stromal progenitor cells and uses thereof
US20110280849A1 (en) * 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
PT2556145T (pt) 2010-04-07 2016-10-25 Anthrogenesis Corp Angiogénese usando células estaminais placentárias
KR20230096132A (ko) * 2010-07-13 2023-06-29 셀룰래리티 인코포레이티드 천연 킬러 세포의 생성 방법
EP2651452A4 (en) 2010-12-17 2014-05-07 Anthrogenesis Corp TREATMENT OF BACKBONE INJURIES AND TRAUMATIC BRAIN DAMAGES WITH ADHESIVE CELLS DERIVED FROM AMNION
KR20210144909A (ko) * 2010-12-17 2021-11-30 안트로제네시스 코포레이션 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료
US20120171180A1 (en) * 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising amnion derived adherent cells and platelet-rich plasma
US9925221B2 (en) * 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
US20150225697A1 (en) * 2012-08-13 2015-08-13 Anthrogenesis Corporation Natural killer cells and uses thereof
US20160166618A1 (en) * 2012-10-19 2016-06-16 Anthrogenesis Corproation Treatment of pain using amnion derived adherent cells

Also Published As

Publication number Publication date
MX2021003799A (es) 2021-06-04
US20160279171A1 (en) 2016-09-29
KR20240023709A (ko) 2024-02-22
EP3068432A2 (en) 2016-09-21
US20190117705A1 (en) 2019-04-25
JP2024016037A (ja) 2024-02-06
AU2020202182A1 (en) 2020-04-16
AU2022215291A1 (en) 2022-09-01
AU2014348454A1 (en) 2016-06-02
WO2015073800A8 (en) 2015-12-17
JP2020019777A (ja) 2020-02-06
JP2022020622A (ja) 2022-02-01
KR20210121277A (ko) 2021-10-07
CN113679740A (zh) 2021-11-23
JP2016537362A (ja) 2016-12-01
CA2930573A1 (en) 2015-05-21
KR20160098244A (ko) 2016-08-18
MX2016006270A (es) 2016-09-07
CA2930573C (en) 2023-12-05
ZA201603270B (en) 2022-09-28
WO2015073800A2 (en) 2015-05-21
AU2022215291A9 (en) 2022-11-24
EP3068432A4 (en) 2017-04-19
CN105916521A (zh) 2016-08-31
WO2015073800A3 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
JP2024016037A5 (enExample)
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
MX2017015239A (es) Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
TN2011000174A1 (en) Compounds that expand hematopoietic stem cells
WO2017077394A3 (en) Materials and methods for treatment of hemoglobinopathies
MX2018006789A (es) Receptores quimericos modificados y composiciones y metodos relacionados.
MX2024000151A (es) Composiciones y usos de las mismas para el tratamiento de afecciones malignas de celulas t usando terapias de celulas adoptivas.
MX2018005618A (es) Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
BR112018076306A2 (pt) composições e métodos para a supressão de células cd117+
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
WO2016135559A3 (en) Materials and methods for treatment of human genetic diseases including hemoglobinopathies
JP2014087372A5 (enExample)
JP2015131795A5 (enExample)
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
HRP20230424T1 (hr) Postupci i pripravci za prirodnoubilačke stanice
PH12018500371B1 (en) Clinical formulations
CO6630117A2 (es) Anticuerpos contra cxcr4
EA201790025A1 (ru) Создание банка мезенхимальных стромальных клеток из объединенных мононуклеарных клеток нескольких доноров костного мозга
NZ741724A (en) Renal cell populations and uses thereof
NZ747910A (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
RU2016123361A (ru) Композиции, включающие клетки плацентарного перфузата человека
FI3325612T3 (fi) Menetelmiä ja kompositioita kantasolutransplantaatiota varten
AR113562A1 (es) Método para inhibir la angiogénesis
IN2014DN08964A (enExample)